市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Ultragenyx Pharmaceutical Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | -2.6 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -2.6 |
| 时机 35% | 1.7 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 0.5 |
| 技术平均移动指标 参考 | 3.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.5% |
| 支柱一致性 | ×0.85 |
| 不计入评分 | |
| 价格波动 参考 | 1.5 |
| 最终评分 | -0.33 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.20% |
| 机构持股比例 | 99.43% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sands Capital Management, Llc | 30 Jun 2026 | 3,158,368 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,717,505 |
该时间范围内无数据。
该时间范围内无数据。
投资组合